Cluster Randomized Trial of Reablement Strategies Targeting Sarcopenia (ReStart-S) in Long-Term Care Settings

Clicks: 2
ID: 315427
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #122 of 130 articles by views in the journals of gerontology series a, biological sciences and medical sciences

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 130 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Sarcopenia prevalence is high in long-term care settings (LTCS), yet existing guidelines often overlook this population. The Reablement Strategies targeting Sarcopenia (ReStart-S) program was developed to address this gap. This study evaluated its effects on muscle outcomes, physical performance, quality of life (QoL), and a blood biomarker. Methods A cluster-randomized trial was conducted in LTCS across Udupi and neighbouring districts. Sarcopenic older adults (≥60 years, Barthel Index ≥60, Mini-Cog ≥3, AWGS-2019 criteria) were recruited. LTCS were randomized into intervention (IG) and control (CG) groups. IG received a 6-week ReStart-S program, while CG continued usual activities. Outcomes at baseline, 6, 12, and 18 weeks included handgrip strength (HGS, primary outcome), skeletal muscle index, Short Physical Performance Battery (SPPB), SarQoL, and C-terminal Agrin Fragment (CAF; not assessed at 12 weeks). Linear mixed models evaluated group*time interactions with Bonferroni correction. Results Of 12 LTCS screened, 7 were eligible; 78 participants enrolled (IG = 39; CG = 39). CG was older than IG (74.3 ± 9.4 vs. 67.9 ± 6.0; p < 0.001). Significant group*time interaction was observed for HGS (F = 5.524; p = 0.001), improving at 12 (2.49; 95% CI: 1.16–3.82; p < 0.001) and 18 weeks (2.14; 0.79–3.48; p = 0.002). SPPB improved at 6, 12, and 18 weeks (all p < 0.001). SarQoL improved at all follow-ups (all p < 0.001). Skeletal muscle index improved at 18 weeks (0.20; p = 0.011). CAF decreased at 18 weeks (-61.77; p < 0.001). Conclusion ReStart-S improved muscle strength, physical performance, and QoL, reduced CAF, and showed delayed muscle mass gains, supporting its role in sarcopenia care in LTCS.
Reference Key
openalex_W7162957779 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Prabal Kumar, Shashikiran Umakanth, Kusumakshi Nayak, Olivier Bruyère, Vennila Jaganathan, Girish Nandakumar
Journal the journals of gerontology series a, biological sciences and medical sciences
Year 2026
DOI
10.1093/gerona/glag141
URL
https://doi.org/10.1093/gerona/glag141
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.